Onkologi (pediatri)
Behandling av anemi
Erytropoiese-stimulerende midler
Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (åpner nytt vindu)
Kilde: Hematology 2007;12(6):533-41.
Arkiv: PubMed 17852440
DOI: 10.1080/10245330701521572
https://www.ncbi.nlm.nih.gov/pubmed/17852440 (åpner nytt vindu)
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (åpner nytt vindu)
Kilde: Cancer 2012;118(3):848-55.
Arkiv: PubMed 21751205
DOI: 10.1002/cncr.26341
https://www.ncbi.nlm.nih.gov/pubmed/21751205 (åpner nytt vindu)
Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (åpner nytt vindu)
Kilde: Pediatr Hematol Oncol 2008;25(6):509-21.
Arkiv: PubMed 18728970
DOI: 10.1080/08880010802235132
https://www.ncbi.nlm.nih.gov/pubmed/18728970 (åpner nytt vindu)
Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (åpner nytt vindu)
Kilde: Pediatr Hematol Oncol 2011;28(6):461-8.
Arkiv: PubMed 21707225
DOI: 10.3109/08880018.2011.570857
https://www.ncbi.nlm.nih.gov/pubmed/21707225 (åpner nytt vindu)
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (åpner nytt vindu)
Kilde: J Clin Oncol 2010;28(13):2239-45.
Arkiv: PubMed 20368566
DOI: 10.1200/JCO.2009.25.1835
https://www.ncbi.nlm.nih.gov/pubmed/20368566 (åpner nytt vindu)
Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (åpner nytt vindu)
Kilde: Asian Pac J Cancer Prev 2011;12(6):1573-6.
Arkiv: PubMed 22126501
https://www.ncbi.nlm.nih.gov/pubmed/22126501 (åpner nytt vindu)
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (åpner nytt vindu)
Kilde: Curr Med Res Opin 2009;25(9):2109-20.
Arkiv: PubMed 19601709
DOI: 10.1185/03007990903084164
https://www.ncbi.nlm.nih.gov/pubmed/19601709 (åpner nytt vindu)
Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (åpner nytt vindu)
Kilde: J Support Oncol 2005;3(6 Suppl 4):10-1.
Arkiv: PubMed 16355549
https://www.ncbi.nlm.nih.gov/pubmed/16355549 (åpner nytt vindu)
The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (åpner nytt vindu)
Kilde: Iran J Ped Hematol Oncol 2014;4(4):151-9.
Arkiv: PubMed 25598955
https://www.ncbi.nlm.nih.gov/pubmed/25598955 (åpner nytt vindu)
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (åpner nytt vindu)
Kilde: Pediatr Blood Cancer 2009;53(1):7-12.
Arkiv: PubMed 19229970
DOI: 10.1002/pbc.21953
https://www.ncbi.nlm.nih.gov/pubmed/19229970 (åpner nytt vindu)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (åpner nytt vindu)
Kilde: Cancer 2013;119(1):107-14.
Arkiv: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (åpner nytt vindu)
Erythropoietic growth factors for children with cancer: a systematic review of the literature. (åpner nytt vindu)
Kilde: Curr Med Res Opin 2007;23(11):2841-7.
Arkiv: PubMed 17910805
DOI: 10.1185/030079907x242601
https://www.ncbi.nlm.nih.gov/pubmed/17910805 (åpner nytt vindu)
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (åpner nytt vindu)
Kilde: J Clin Oncol 2006;24(22):3583-9.
Arkiv: PubMed 16877725
DOI: 10.1200/JCO.2005.03.4371
https://www.ncbi.nlm.nih.gov/pubmed/16877725 (åpner nytt vindu)
The role of recombinant erythropoietin in childhood cancer. (åpner nytt vindu)
Kilde: Oncologist 2008;13(2):157-66.
Arkiv: PubMed 18305061
DOI: 10.1634/theoncologist.2007-0126
https://www.ncbi.nlm.nih.gov/pubmed/18305061 (åpner nytt vindu)
Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (åpner nytt vindu)
Kilde: MEDICC Rev 2010;12(3):27-31.
Arkiv: PubMed 20697335
DOI: 10.37757/MR2010.V12.N3.7
https://www.ncbi.nlm.nih.gov/pubmed/20697335 (åpner nytt vindu)
A single institutional experience: is epoetin alpha effective in anemic children with cancer? (åpner nytt vindu)
Kilde: Pediatr Hematol Oncol 2004;21(1):1-8.
Arkiv: PubMed 14660300
https://www.ncbi.nlm.nih.gov/pubmed/14660300 (åpner nytt vindu)
Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (åpner nytt vindu)
Kilde: Pediatr Hematol Oncol 2014;31(5):442-7.
Arkiv: PubMed 24088186
DOI: 10.3109/08880018.2013.824527
https://www.ncbi.nlm.nih.gov/pubmed/24088186 (åpner nytt vindu)
Early epoetin alfa treatment in children with solid tumors. (åpner nytt vindu)
Kilde: Med Pediatr Oncol 2002;39(4):459-62.
Arkiv: PubMed 12203664
DOI: 10.1002/mpo.10186
https://www.ncbi.nlm.nih.gov/pubmed/12203664 (åpner nytt vindu)
Intravenøse jernpreparater
Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (åpner nytt vindu)
Kilde: Pediatr Blood Cancer 2011;56(4):615-9.
Arkiv: PubMed 21298748
DOI: 10.1002/pbc.22930
https://www.ncbi.nlm.nih.gov/pubmed/21298748 (åpner nytt vindu)
Intravenous iron sucrose for children with iron deficiency anemia. (åpner nytt vindu)
Kilde: J Pediatr Hematol Oncol 2017;39(5):e259-62.
Arkiv: PubMed 28562517
DOI: 10.1097/MPH.0000000000000879
https://www.ncbi.nlm.nih.gov/pubmed/28562517 (åpner nytt vindu)
Advances in Pediatric Intravenous Iron Therapy. (åpner nytt vindu)
Kilde: Pediatr Blood Cancer 2016;63(1):11-6.
Arkiv: PubMed 26376214
DOI: 10.1002/pbc.25752
https://www.ncbi.nlm.nih.gov/pubmed/26376214 (åpner nytt vindu)
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (åpner nytt vindu)
Kilde: Cochrane Database Syst Rev 2016;(2):CD009624.
Arkiv: PubMed 26845108
DOI: 10.1002/14651858.CD009624.pub2
https://www.ncbi.nlm.nih.gov/pubmed/26845108 (åpner nytt vindu)
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (åpner nytt vindu)
Kilde: J Clin Oncol 2008;26(10):1619-25.
Arkiv: PubMed 18375891
DOI: 10.1200/JCO.2007.12.2051
https://www.ncbi.nlm.nih.gov/pubmed/18375891 (åpner nytt vindu)
Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (åpner nytt vindu)
Kilde: Pediatr Blood Cancer 2013;60(11):1747-52.
Arkiv: PubMed 23832487
DOI: 10.1002/pbc.24676
https://www.ncbi.nlm.nih.gov/pubmed/23832487 (åpner nytt vindu)